Annals of Surgical Oncology

, Volume 16, Issue 1, pp 226–227 | Cite as

Perioperative Chemotherapy for Gastric Cancer

  • E. Fatourou
  • A. Macheras
  • E. P. Misiakos
  • T. Liakakos
Gastrointestinal Oncology


Gastric Cancer Diffuse Gastric Cancer Hereditary Diffuse Gastric Cancer Discriminatory Accuracy Common Complex Disease 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Persiani R, Rausei S, Pozzo C, et al. 7-Year survival results of perioperative chemotherapy with epidoxorubicin, etoposide, and cisplatin (EEP) in locally advanced resectable gastric cancer: up-to-date analysis of a phase-II study. Ann Surg Oncol 2008 Jun 10. [Epub ahead of print]Google Scholar
  2. 2.
    Liakakos T, Roukos DH. More controversy than ever-challenges and promises towards personalized treatment of gastric cancer. Ann Surg Oncol 2008;15:956–60CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Briasoulis E, Liakakos T, Dova L, et al. Selecting a specific pre- or postoperative adjuvant therapy for individual patients with operable gastric cancer. Expert Rev Anticancer Ther 2006; 6:931–9CrossRefPubMedGoogle Scholar
  4. 4.
    Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355:11–20CrossRefPubMedGoogle Scholar
  5. 5.
    Briasoulis E, Fatouros M, Roukos DH. Level I evidence in support of perioperative chemotherapy for operable gastric cancer: sufficient for wide clinical use? Ann Surg Oncol 2007; 14:2691–5CrossRefPubMedGoogle Scholar
  6. 6.
    Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007; 357:1810–20CrossRefPubMedGoogle Scholar
  7. 7.
    Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinomas of the stomach or gastroesophageal junction. N Engl J Med 2001; 345:725–30CrossRefPubMedGoogle Scholar
  8. 8.
    Roukos DH. Adjuvant chemoradiotherapy in gastric cancer: wave goodbye to extensive surgery? Ann Surg Oncol 2002; 9:220–1CrossRefPubMedGoogle Scholar
  9. 9.
    Roukos DH, Murray S, Briasoulis E. Molecular genetic tools shape a roadmap towards a more accurate prognostic prediction and personalized management of cancer. Cancer Biol Ther 2007;6:308–12CrossRefPubMedGoogle Scholar
  10. 10.
    Roukos DH, Ziogas D. Human genetic and structural genomic variation: would genome-wide association studies be the solution for cancer complexity like Alexander the Great for the “Gordian Knot”? Ann Surg Oncol 2008 Jul 9. [Epub ahead of print]. DOI:  10.1245/s10434-008-0056-2
  11. 11.
    Roukos DH, Lykoudis E, Liakakos T. Genomics and challenges toward personalized breast cancer local control. J Clin Oncol 2008; 26(26):4360–4361CrossRefPubMedGoogle Scholar
  12. 12.
    Norton JA, Ham CM, Van Dam J, et al. CDH1 truncating mutations in the E-cadherin gene: an indication for total gastrectomy to treat hereditary diffuse gastric cancer. Ann Surg 2007;245:873–9CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Roukos DH, Briasoulis E. Individualized preventive and therapeutic management of hereditary breast ovarian cancer. Nat Clin Pract Oncol 2007; 4:578–90CrossRefPubMedGoogle Scholar
  14. 14.
    Roukos DH. Linking contralateral breast cancer with genetics. Radiother Oncol 2008; 86:139–41CrossRefPubMedGoogle Scholar
  15. 15.
    Roukos DH. Prognosis of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 2007; 357:1555–6; author reply 1556CrossRefPubMedGoogle Scholar
  16. 16.
    Fatouros M, Baltoyiannis G, Roukos DH. The predominant role of surgery in the prevention and new trends in the surgical treatment of women with BRCA1/2 mutations. Ann Surg Oncol 2008; 15:21–33CrossRefPubMedGoogle Scholar
  17. 17.
    Agnantis NJ, Paraskevaidis E, Roukos D. Preventing breast, ovarian cancer in BRCA carriers: rational of prophylactic surgery and promises of surveillance. Ann Surg Oncol 2004;11:1030–4CrossRefPubMedGoogle Scholar
  18. 18.
    Roukos DH. Early-stage gastric cancer: a highly treatable disease. Ann Surg Oncol 2004; 11:127–9CrossRefPubMedGoogle Scholar
  19. 19.
    Roukos DH, Lorenz M, Encke A. Evidence of survival benefit of extended (D2) lymphadenectomy in western patients with gastric cancer based on a new concept: a prospective long-term follow-up study. Surgery 1998;123:573–8CrossRefPubMedGoogle Scholar
  20. 20.
    Roukos DH. Current advances and changes in treatment strategy may improve survival and quality of life in patients with potentially curable gastric cancer. Ann Surg Oncol 1999; 6:46–56CrossRefPubMedGoogle Scholar
  21. 21.
    Roukos DH, Kappas AM, Agnantis NJ. Perspectives and risks of breast-conservation therapy for breast cancer. Ann Surg Oncol 2003; 10:718–21CrossRefPubMedGoogle Scholar
  22. 22.
    Fatouros M, Roukos DH, Arampatzis I, et al. Factors increasing local recurrence in breast-conserving surgery. Expert Rev Anticancer Ther 2005;5:737–45CrossRefPubMedGoogle Scholar
  23. 23.
    Roukos DH. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 2008; 358:197, author reply 198Google Scholar
  24. 24.
    Roukos DH. Breast-cancer stromal cells with TP53 mutations. N Engl J Med 2008 10;358:1636; author reply 1636Google Scholar
  25. 25.
    Roukos DH. Innovative genomic-based model for personalized treatment of gastric cancer: integrating current standards and new technologies. Expert Rev Mol Diagn 2008; 8:29–39CrossRefPubMedGoogle Scholar
  26. 26.
    Roukos DH. Genetics and genome-wide association studies: surgery-guided algorithm and promise for future breast cancer personalized surgery. Expert Rev Mol Diagn 2008; 8(5):587–597CrossRefPubMedGoogle Scholar
  27. 27.
    Roukos DH. Personal genomics and genome-wide association studies: novel discoveries but limitations for practical personalized medicine. Ann Surg Oncol 2008. DOI:  10.1245/s10434-008-0190-6

Copyright information

© Society of Surgical Oncology 2008

Authors and Affiliations

  • E. Fatourou
    • 1
  • A. Macheras
    • 2
  • E. P. Misiakos
    • 2
  • T. Liakakos
    • 2
  1. 1.Department of HepatologyIppokrateio Hospital University of AthensAthensGreece
  2. 2.3rd Department of Surgery, School of MedicineAthens UniversityAthensGreece

Personalised recommendations